Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Shionogi & Co ( (JP:4507) ) is now available.
Shionogi & Co., Ltd. reported its consolidated financial results for the second quarter of fiscal year 2025, showing a slight decrease in revenue and operating profit compared to the same period last year. Despite these declines, the company experienced growth in profit before tax and comprehensive income, indicating a positive financial trajectory. The company also announced a revision in its financial forecast for the year ending March 31, 2026, with expectations of increased revenue and profit. The inclusion of Torii Pharmaceutical Co., Ltd. as a subsidiary marks a strategic expansion in Shionogi’s operations, potentially enhancing its market position and offering new opportunities for growth.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen2770.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a pharmaceutical company listed on the Tokyo Stock Exchange, primarily involved in the research, development, and distribution of pharmaceutical products. The company focuses on creating innovative medicines and has a significant presence in the global pharmaceutical market.
YTD Price Performance: 13.08%
Average Trading Volume: 2,301,334
Technical Sentiment Signal: Buy
Current Market Cap: Yen2148.7B
See more insights into 4507 stock on TipRanks’ Stock Analysis page.